X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs CADILA HEALTHCARE - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA CADILA HEALTHCARE DISHMAN PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 25.1 19.1 131.2% View Chart
P/BV x 3.3 4.3 77.2% View Chart
Dividend Yield % 0.7 0.9 70.3%  

Financials

 DISHMAN PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
CADILA HEALTHCARE
Mar-18
DISHMAN PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs374558 67.1%   
Low Rs129362 35.7%   
Sales per share (Unadj.) Rs197.8116.3 170.1%  
Earnings per share (Unadj.) Rs21.217.9 118.7%  
Cash flow per share (Unadj.) Rs34.723.1 150.1%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.80.8 104.4%  
Book value per share (Unadj.) Rs179.985.4 210.6%  
Shares outstanding (eoy) m80.691,023.74 7.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.0 32.2%   
Avg P/E ratio x11.925.7 46.1%  
P/CF ratio (eoy) x7.219.9 36.5%  
Price / Book Value ratio x1.45.4 26.0%  
Dividend payout %9.419.6 48.1%   
Avg Mkt Cap Rs m20,306470,664 4.3%   
No. of employees `0000.811.8 7.0%   
Total wages/salary Rs m5,35518,545 28.9%   
Avg. sales/employee Rs Th19,252.710,072.7 191.1%   
Avg. wages/employee Rs Th6,459.51,569.1 411.7%   
Avg. net profit/employee Rs Th2,064.11,547.7 133.4%   
INCOME DATA
Net Sales Rs m15,961119,049 13.4%  
Other income Rs m2651,132 23.4%   
Total revenues Rs m16,226120,181 13.5%   
Gross profit Rs m4,10328,475 14.4%  
Depreciation Rs m1,0915,388 20.2%   
Interest Rs m944911 103.7%   
Profit before tax Rs m2,33423,308 10.0%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6245,644 11.0%   
Profit after tax Rs m1,71118,292 9.4%  
Gross profit margin %25.723.9 107.5%  
Effective tax rate %26.724.2 110.4%   
Net profit margin %10.715.4 69.8%  
BALANCE SHEET DATA
Current assets Rs m11,01882,005 13.4%   
Current liabilities Rs m9,51760,720 15.7%   
Net working cap to sales %9.417.9 52.6%  
Current ratio x1.21.4 85.7%  
Inventory Days Days11073 151.1%  
Debtors Days Days3598 35.4%  
Net fixed assets Rs m16,30483,703 19.5%   
Share capital Rs m1611,024 15.8%   
"Free" reserves Rs m12,90786,421 14.9%   
Net worth Rs m14,51687,445 16.6%   
Long term debt Rs m4,18925,551 16.4%   
Total assets Rs m29,805180,653 16.5%  
Interest coverage x3.526.6 13.1%   
Debt to equity ratio x0.30.3 98.8%  
Sales to assets ratio x0.50.7 81.3%   
Return on assets %8.910.6 83.8%  
Return on equity %11.820.9 56.4%  
Return on capital %17.522.0 79.7%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95242,683 11.6%   
Fx outflow Rs m69711,242 6.2%   
Net fx Rs m4,25531,441 13.5%   
CASH FLOW
From Operations Rs m2,7869,193 30.3%  
From Investments Rs m-1,529-9,737 15.7%  
From Financial Activity Rs m-941515 -182.7%  
Net Cashflow Rs m316-29 -1,091.0%  

Share Holding

Indian Promoters % 61.4 74.8 82.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 8.3 44.6%  
FIIs % 12.7 5.9 215.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 11.0 200.9%  
Shareholders   46,261 44,069 105.0%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ELDER PHARMA  TTK HEALTHCARE  SHASUN PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS